Key result
Phosphatidylethanolamine-dependent antiphospholipid antibodies selectively inhibit the protein C pathway, promoting thrombosis.
Phosphatidylethanolamine (PE) is an important membrane component for supporting activated protein C anticoagulant activity but has little influence on prothrombin activation. This difference constitutes a potential mechanism for selective inhibition of the protein C anticoagulant pathway by lupus anticoagulants and/or antiphospholipid antibodies. In this study, we demonstrate that the presence of PE augments lupus anticoagulant activity. In the plasma of some patients with lupus anticoagulants, activated protein C anticoagulant activity is more potently inhibited than prothrombin activation. As a result, in the presence of activated protein C and PE, these patient plasmas clot faster than normal plasma. Patients with minimal lupus anticoagulant activity are identified whose plasma potently inhibits activated protein C anticoagulant activity. This process is also PE dependent. In three patient plasmas, these phenomena are shown to be due to immunoglobulins. The PE requirement in the expression of activated protein C anticoagulant activity and the PE dependence of some antiphospholipid antibodies provide a mechanistic basis for the selective inhibition of the protein C pathway. Inhibition of activated protein C function may be a common mechanism contributing to increased thrombotic risk in certain patients with antiphospholipid antibodies.
No takes yet. Share an insight, caveat, or question.
Smirnov et al. (1995) studied Antiphospholipid antibodies / lupus anticoagulants. Phosphatidylethanolamine (PE) was evaluated on Activated protein C anticoagulant activity and prothrombin activation. Phosphatidylethanolamine dependence of some antiphospholipid antibodies provides a mechanistic basis for selective inhibition of the protein C pathway, potentially increasing thrombotic risk.
Synapse has enriched 5 related papers. Consider them for comparative context: